Keyword: Lightstone Ventures
Nuvaira has raised $79 million in equity financing to continue late-stage clinical development of its device-based treatment for COPD in the U.S.
The device is designed to enable the remote monitoring of heart failure patients and thereby improve outcomes.
The series C round equips Claret to try to expand access to a device that protects patients from neurological and neurocognitive damage.
Atlas Venture, Lightstone Ventures and OrbiMed put up the cash to equip Gemini to turn advances in our understanding of AMD genetics into a pipeline.
VC Lightstone has $250 million in the bank for life science research.
Disarm Therapeutics has seen a strong $30 million series A round as it looks for a breakthrough approach in axonal degeneration.
Japanese Big Pharma Takeda and VC Lightstone have come together to launch Cerevance, a newco focused on neuroscience R&D for neurological and psychiatric disorders that will get the help of U.K. scientists and be headed up by Brad Margus.